Table 2.
Clinical and pathologic characteristics according to NLR, LMR or PLR in 109 patients with ovarian clear cell carcinoma
| Characteristics | NLR-low (<2.3) |
NLR-high (≥2.3) |
P | LMR-low (<4.2) |
LMR-high (≥4.2) |
P |
PLR-low (<123.6) |
PLR-high (≥123.6) |
P |
|---|---|---|---|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | ||||
| Age (yr) | 0.786 | 0.638 | 0.453 | ||||||
| <50 | 16 (48.5) | 39 (51.3) | 36 (52.2) | 19 (47.5) | 10 (58.8) | 45 (48.9) | |||
| ≥50 | 17 (51.5) | 37 (48.7) | 33 (47.8) | 21 (52.5) | 7 (41.2) | 47 (51.1) | |||
| FIGO stage | 0.005 | 0.026 | 0.585 | ||||||
| I/II | 26 (78.8) | 38 (50.0) | 35 (50.7) | 29 (72.5) | 11 (64.7) | 53 (57.6) | |||
| III/IV | 7 (21.2) | 38 (50.0) | 34 (49.3) | 11 (27.5) | 6 (35.3) | 39 (42.4) | |||
| LN metastasis | 0.316 | 0.031 | 0.094 | ||||||
| No | 28 (84.8) | 58 (76.3) | 50 (72.5) | 36 (90.0) | 16 (94.1) | 70 (76.1) | |||
| Yes | 5 (15.2) | 18 (23.7) | 19 (27.5) | 4 (10.0) | 1 (5.9) | 22 (23.9) | |||
| Malignant ascites | 0.047 | 0.013 | 0.608 | ||||||
| No | 26 (78.8) | 45 (59.2) | 39 (56.5) | 32 (80.0) | 12 (70.6) | 59 (64.1) | |||
| Yes | 7 (21.2) | 31 (40.8) | 30 (43.5) | 8 (20.0) | 5 (29.4) | 33 (35.9) | |||
| Endometriosis | 0.712 | 0.634 | 0.267 | ||||||
| No | 25 (13.8) | 60 (23.1) | 55 (79.7) | 30 (75.0) | 15 (88.2) | 70 (76.1) | |||
| Yes | 8 (86.2) | 16 (76.9) | 14 (20.3) | 10 (25.0) | 2 (11.8) | 22 (23.9) | |||
| CA-125 (Unit/mL) | 0.269 | 0.113 | 0.173 | ||||||
| <88.2 | 19 (57.6) | 35 (46.1) | 29 (42.0) | 25 (62.5) | 11 (64.7) | 43 (46.7) | |||
| ≥88.2 | 14 (42.4) | 41 (53.9) | 40 (58.0) | 15 (37.5) | 6 (35.3) | 49 (53.3) | |||
| Residual mass | 0.254 | 0.178 | 0.150 | ||||||
| <1 cm | 28 (84.8) | 57 (75.0) | 51 (73.9) | 34 (85.0) | 11 (64.7) | 74 (80.4) | |||
| ≥1 cm | 5 (15.2) | 19 (25.0) | 18 (26.1) | 6 (15.0) | 6 (35.3) | 18 (19.6) | |||
| Platinum response | 0.008 | 0.021 | 0.870 | ||||||
| Sensitive | 31 (93.9) | 54 (71.1) | 49 (71.0) | 36 (90.0) | 13 (76.5) | 72 (78.3) | |||
| Resistant | 2 (6.1) | 22 (28.9) | 20 (29.0) | 4 (10.0) | 4 (23.5) | 20 (21.7) |
NLR, neutrophil-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; PLR, platelet-lymphocyte ratio; FIGO, The International Federation of Gynecology and Obstetrics; LN, lymph node; CA-125, cancer antigen 125